Subject: Request for NYSE / SEC / counsel correspondence concerning cannabis operations, Schedule III, and deconsolidation

To: Glass House Brands Inc. / Counsel / Exchange Listing Counsel

Please produce all records concerning NYSE listing or continued-listing review, SEC comments/correspondence, and counsel analyses relating to:

1. Glass House Brands' NYSE listing application and approval.
2. Medical cannabis Schedule III reclassification.
3. Separation of medical cannabis from adult-use or dual-use cannabis operations.
4. Glass House Retail deconsolidation and retained non-voting/exchangeable units.
5. Whether Glass House Brands consolidates or controls any entity involved in non-medical/adult-use marijuana.
6. NYSE suitability, continued-listing risk, qualitative listing standards, and public-interest considerations.
7. Public statements about interstate commerce, medical cannabis export to Europe, hemp/CBD export, and related opportunities.
8. Any SEC, NYSE, auditor, underwriter, bank, counsel, or investor comments about the transaction.